Arrowhead Pharmaceuticals Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Arrowhead Pharmaceuticals Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 09 Dec 2022 | Lorem |
| RNA therapeutics R&D landscape to expand with newer modalities in oncology and other indications in 2022 | 21 Dec 2021 | Manasi Vaidya |
| LoA Update: Arrowhead’s Phase I/II ARO-HSD chances of progressing to next stage of development rises by 5 points after positive interim data | 29 Jun 2021 | Reynald Castaneda |
| Arrowhead’s interim Phase II data in A1AD liver disease lacks correlation with potential fibrosis impact, investigators say | 20 Nov 2020 | Reynald Castaneda |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer